Inhibition of cyclin-dependent kinases (CDKs) with small molecules has been suggested as
a strategy for treatment of cancer, based on deregulation of CDKs commonly found in many …

Pharmacological inhibitors of cyclin-dependent kinases (CDKs) have a wide therapeutic
potential. Among the CDK inhibitors currently under clinical trials, the 2, 6, 9-trisubstituted …

Abstract Cyclin-dependent kinase 2 (CDK2) is a vital protein for controlling cell cycle
progression that is critically associated with various malignancies and its inhibition could …

Purine inhibitors of cyclin-dependent kinases attract attention as potential anticancer drugs
because their first representative roscovitine recently entered clinical trials. Although well …

Roscovitine is a synthetic inhibitor of cyclin-dependent kinases that is currently undergoing
clinical trials as a candidate drug for some oncological indications. Its discovery prompted …

New diphenyl-1H-pyrazoles were synthesized and screened for CDK2 inhibition where 8d,
9b, 9c, and 9e exhibited promising activity (IC 50= 51.21, 41.36, 29.31, and 40.54 nM …

Several inhibitors of cyclin-dependent kinases (CDKs), including the 2, 6, 9-trisubstituted
purine derivative roscovitine, are currently being evaluated in clinical trials as potential …

Purine inhibitors of cyclin-dependent kinases (CDK) seem to be a potential anticancer drug
candidate as one of the first representatives, roscovitine, is passing Phase II clinical trials for …

Small molecular inhibitors of Cyclin dependent kinases (Cdks) are currently being
developed as anticancer therapeutics due to their antiproliferative properties. The purine …

3, 5, 7-Trisubstituted pyrazolo [4, 3-d] pyrimidines have been identified as potent inhibitors of
cyclin-dependent kinases (CDKs), which are established drug targets. Herein, we describe …